following a full submission:
ofatumumab (Kesimpta®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Two phase III studies demonstrated superiority of ofatumumab in reducing annualised relapse rate when compared with another disease-modifying treatment (DMT) in adult patients with RMS.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
Medicine details
- Medicine name:
- ofatumumab (Kesimpta)
- SMC ID:
- SMC2357
- Indication:
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 July 2021